This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-13 and is reviewed periodically as new material appears.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20 °C or below | Desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity and identity |
| Common synonyms | Thymalfasin, T alpha 1 | Sequence identical to natural fragment |
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
The above discussion is based on the ideal vapour-compression refrigeration cycle, and does not take into account real-world effects like frictional pressure drop in the system, slight thermodynamic irreversibility during the compression of the refrigerant vapor, or non-ideal gas behavior, if any. Vapor compression refrigerators can be arranged in two stages in cascade refrigeration systems, with the second stage cooling the condenser of the first stage. This can be used for achieving very low temperatures. More information about the design and performance of vapor-compression refrigeration systems is available in the classic Perry's Chemical Engineers' Handbook.
It was initially sold in a flask-like container shaped with a narrow neck to prevent moisture from seeping into the product. Another theory is that in 1916, Tanaka Foods developed "Travel Friend"(旅行の友) in cans at the request of the military as a nutritional supplement. This is a blend of dried small fish powder seasoned with soy sauce, sesame, seaweed, and egg. In 1927, a grocery retailer in Fukushima City named Seiichirō Kai developed a mixture consisting of ishimochi (石持 or 石首魚, silver white croaker, Pennahia argentata) with soy sauce seasoning, kelp, and sesame seeds. He founded the Marumiya Food Research Institute. Kai called his product Kore Wa Umai (これは旨い, 'This Is Tasty'); it was popular on its release. Although Kore Wa Umai was initially considered a luxury item for the affluent who were able to consume white rice on a regular basis, it later was made accessible to the Japanese working class.
Several solid-state and vacuum devices have been explored for use in different parts of the UV spectrum. Many approaches seek to adapt visible light-sensing devices, but these can suffer from unwanted response to visible light and various instabilities. Ultraviolet can be detected by suitable photodiodes and photocathodes, which can be tailored to be sensitive to different parts of the UV spectrum. Sensitive UV photomultipliers are available. Spectrometers and radiometers are made for measurement of UV radiation. Silicon detectors are used across the spectrum.
Sources: en.wikipedia.org
In a 2023 interview, Paetongtarn called herself a "socially liberal capitalist". Paetongtarn stated that her party and Srettha Thavisin wants to focus on bread-and-butter issues and improving the economy. She supports "capitalism with empathy" along with gradually raising the minimum wage and implementing a ฿10,000 digital wallet scheme. In May 2024, Paetongtarn told party members at an event held at Pheu Thai headquarters "The law that keeps the Bank of Thailand (BoT) independent from the government...is a problem and a significant obstacle in fixing economic problems", referencing the decade-high interest-rate of 2.50% which Srettha Thavisin believes was hurting small businesses and hurting government efforts to jumpstart an economy he says is in crisis. Paetongtarn said BoT monetary policy "refuses to understand and cooperate" and would hamper efforts to reduce high levels of debt.
Carbamazepine is typically used for the treatment of seizure disorders and neuropathic pain. It is used off-label as a second-line treatment for bipolar disorder and in combination with an antipsychotic in some cases of schizophrenia when treatment with a conventional antipsychotic alone has failed. However, evidence does not support its usage for schizophrenia. It is not effective for absence seizures or myoclonic seizures. Although carbamazepine may have a similar effectiveness (as measured by people continuing to use a medication) and efficacy (as measured by the medicine reducing seizure recurrence and improving remission) when compared to phenytoin and valproate, it is not well-researched which medication is most helpful for people with newly-onset seizures. In the United States, carbamazepine is indicated for the treatment of epilepsy (including partial seizures, generalized tonic-clonic seizures and mixed seizures), and trigeminal neuralgia. Carbamazepine is the only medication that is approved by the Food and Drug Administration for the treatment of trigeminal neuralgia. As of 2014, a controlled release formulation was available for which there is tentative evidence showing fewer side effects and unclear evidence with regard to whether there is a difference in efficacy. In 2016, the FDA approved an intravenous formulation of carbamazepine, also granting it orphan drug status under the trade name Carnexiv, as a short-term replacement therapy for oral carbamazepine in adults with specific types of seizure disorders, who are unable to tolerate the oral formulation.
== Side effects == The most common side effects affecting more than 5% of patients are headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increase, nasal congestion, blood creatine phosphokinase increase, aspartate aminotransferase increase, rhinorrhea, rhinitis, influenza, sinusitis, and blood bilirubin increase.
== Works == West edited and commented on Hesiod's Theogony and Works and Days. In 1967, he published with Reinhold Merkelbach Fragmenta Hesiodea, an edition containing other fragmentary poems attributed to Hesiod. He also edited a book on the fragments of the Hesiodic Catalogue of Women. West edited Homer's Iliad and Odyssey for the Bibliotheca Teubneriana, and the Homeric Hymns for the Loeb Classical Library.
Sources: en.wikipedia.org
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.
Mass spectrometry gives the molecular mass, which is compared with the calculated value. Reversed-phase liquid chromatography shows purity and the presence of related impurities. Peptide mapping can verify the amino acid sequence when a higher level of detail is needed.
It reports the tests the supplier performed, which may vary between laboratories and lots. Methods and acceptance criteria are not standardised across suppliers. Buyers often request the actual chromatograms and spectra rather than a summary statement.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.